Surveillance Solutions for Detection, Discrimination, and Discovery of Emerging SARS-CoV-2 Variants

Jelena Feenstra, PhD

Jelena Feenstra, PhD
Senior Manager, Global Scientific Communications
Thermo Fisher Scientific

The emergence of novel SARS-CoV-2 variants can have profound effects on efforts to fight the ongoing COVID-19 pandemic. According to the US CDC, several Variants of Concern (VOC) / Interest (VOI) are circulating in the U.S., including B.1.1.7 (UK variant), B.1.351 (SA variant), P.1 (Brazilian variant), B.1.526 (NY variant), B.1.427/B.1.429 (California variant). Besides being more transmissible or, potentially more lethal, these VOC may lead to therapy resistance, reduced effectiveness of COVID-19 vaccines or impact performance of diagnostic assays. It is, therefore, of utmost importance to perform genomic surveillance for SARS-CoV-2. In this webinar, we will discuss the different options for the detection, discrimination and discovery of emerging SARS-CoV-2 variants. This may allow public health laboratories to implement different strategies and efficiently utilize their testing resources while scaling up surveillance testing as the world moves from a pandemic to an endemic environment.

Please fill out the form to access this webinar.

(*Indicates a mandatory field)

Intended use and regulatory statements of products vary. For specific intended use and regulatory statements please refer to the Instructions for Use (IFU). Product availability by country varies.